Patents by Inventor Wilhelm Bone
Wilhelm Bone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230046077Abstract: The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1? and/or ?) useful for the treatment of proliferative disorders.Type: ApplicationFiled: February 6, 2020Publication date: February 16, 2023Inventors: Volker Schulze, Anne Mengel, Jens Schroeder, Adelaide Clara Faria Alvares De Lemos, Wilhelm Bone, Ulf Bomer, Detlev Sulzle, Clara Christ, Roman Hillig, Christian Lechner, Steven Corsello, Kasia Handing, Alisha Caliman, Ulrike Rauh, Stefan Kaulfuss, Jérémie Mortier
-
Patent number: 11529356Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 21, 2020Date of Patent: December 20, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 10894784Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: December 15, 2016Date of Patent: January 19, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Volker Schulze, Tobias Heinrich, Florian Prinz, Julien Lefranc, Jens Schröder, Anne Mengel, Wilhelm Bone, Joszef Bálint, Antje Margret Wengner, Knut Eis, Horst Irlbacher, Marcus Koppitz, Ulf Bömer, Benjamin Bader, Hans Briem, Philip Lienau, Clara Christ, Detlef Stöckigt, Roman Hillig
-
Publication number: 20200383991Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 10428044Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: June 17, 2015Date of Patent: October 1, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Keith Graham, Ulrich Klar, Hans Briem, Marion Hitchcock, Lars Bärfacker, Knut Eis, Volker Schulze, Gerhard Siemeister, Wilhelm Bone, Jens Schröder, Simon Holton, Philip Lienau, René Tempel, Helmut Sonnenschein, Jozsef Bálint, Heinz Graubaum
-
Patent number: 10350206Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.Type: GrantFiled: September 17, 2015Date of Patent: July 16, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Anne Mengel, Hans-Georg Lerchen, Manfred Möwes, Thomas Müller, Lars Bärfacker, Marion Hitchcock, Arwed Cleve, Joachim Kuhnke, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Ursula Mönning, Simon Holton
-
Publication number: 20190047980Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2016Publication date: February 14, 2019Inventors: Volker SCHULZE, Tobias HEINRICH, Florian PRINZ, Julien LEFRANC, Jens SCHRÖDER, Anne MENGEL, Wilhelm BONE, Joszef BÁLINT, Antje Margret WENGNER, Knut EIS, Horst IRLBACHER, Marcus KOPPITZ, Ulf BÖMER, Benjamin BADER, Hans BRIEM, Philip LIENAU, Clara CHRIST, Detlef STÖCKIGT, Roman HILLIG
-
Patent number: 10155004Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.Type: GrantFiled: April 4, 2017Date of Patent: December 18, 2018Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
-
Publication number: 20180256591Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9993484Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2015Date of Patent: June 12, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20170305882Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: October 26, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Hans-Georg LERCHEN, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNÁNDEZ-MONTÁLVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
-
Publication number: 20170275270Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 15, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Lars BÄRFACKER, Thomas MÜLLER, Anne MENGEL, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
-
Publication number: 20170275269Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
-
Publication number: 20170273980Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Hans-Georg LERCHEN, Manfred MÖWES, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Joachim KUHNKE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
-
Patent number: 9765058Abstract: Compounds of formula (I), and their use as pharmaceuticals.Type: GrantFiled: June 17, 2014Date of Patent: September 19, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Marion Hitchcock, Anne Mengel, Anja Richter, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Simon Holton, Cornelia Preuβe, Ursula Mönning
-
Patent number: 9745285Abstract: Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: June 17, 2014Date of Patent: August 29, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Anne Mengel, Marion Hitchcock, Anja Richter, Lars Bärfacker, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Simon Holton, Cornelia Preuβe, Ursula Mönning
-
Publication number: 20170216304Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9717739Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.Type: GrantFiled: June 4, 2015Date of Patent: August 1, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
-
Publication number: 20170202857Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.Type: ApplicationFiled: April 4, 2017Publication date: July 20, 2017Inventors: Wolfgang SCHWEDE, Ulrich KLAR, Carsten MOLLER, Andrea ROTGERI, Wilhelm BONE